COVID-19 vaccine candidate being developed by Johnson & Johnson JNJ
An emergency authorization may be granted to the subsidiary Jensen Pharmacectica by UK regulators, to promote the country’s large-scale vaccination program amid an increase in coronovirus cases.
John Bell, professor of medicine at the University of Oxford and an adviser at the UK Vaccine Taskforce, told the Daily Telegraph, “My prediction is that it will work well, although we need to wait for the results of the test. “
He said: “I think they will have supplies available to the UK in a timeframe that will allow us to catch the mid-February target of getting the numbers. I think we will have more people in the UK getting vaccinated What can we do for him, it can have a good effect on him. ”
opinion: There is only a slim chance that the vaccine will stop the COVID epidemic this year
A spokesperson for Janssen said it would be premature for the company to comment on the production of its vaccine, until results from its ongoing Phase 3 clinical study are anticipated, which are anticipated later this month .
“Jenson will continue to work with MHRA [Medicines and Healthcare products Regulatory Agency] The spokesperson said that a national marketing authority in the UK is committed to carrying out an inexpensive COVID-19 vaccine to the public to complete the rolling review process for the application and for emergency epidemic use.
If the data indicates that the vaccine is safe and effective, J&J expects to submit an Emergency Use Authority application to the US Food and Drug Administration in February.
The UK government has ordered 30 million doses of the Jensen vaccine, with an option to purchase over 22 million. The candidate for the vaccine is a single-dose shot, developed by Biotech Modern mRNA.
And the American pharmaceutical company Pfizer PFE,
And its German partner BioNTech BNTX,
It can be safely stored and transported at standard refrigerator temperatures, while the Pfizer-Bayonet vaccine requires storage at a minimum temperature of 70C.
If Janssen’s vaccine candidate is authorized by UK regulators, it will become the third large-scale vaccine to be rolled out in the country after the Pfizer-Biotech vaccine and developed by drug company AstraZenecide AZN.
With the University of Oxford, and will help speed the campaign for vaccination to the public.
According to the government more than 1.3 million people in the UK have already received a shot at either the Pfizer-BioNotech vaccine or the AstraZeneca-Oxford vaccine. It intends to vaccinate 13 million of the most vulnerable people in Britain by mid-February, a goal that England’s Chief Medical Officer, Prof. Chris Whitty has called it “realistic, but not easy”.
Read: Britain becomes the first country to have the AstraZeneca-Oxford vaccine imminent as a teamer lockdown
Prime Minister Boris Johnson warned on Wednesday that “there was a race to rapidly vaccinate vulnerable viruses that could reach those viruses.”
“Every needle makes a difference in every hand,” Johnson told lawmakers.
According to government data, as of Wednesday, 1,041 people had died within 28 days of testing positive for coronavirus.
The National Health Service said that in an effort to promote a large-scale immunization campaign, some general practice surgeries would be permitted to operate the AstraZeneca-Oxford vaccine from Thursday.
The NHS said seven vaccination centers will be in place, with many more sites coming online next week, as well as more hospitals, GP-led services and several pilot pharmacy vaccine services.
Read: Fauci reportedly says that the US will not extend the interval between vaccine doses
Last week, the MHRA, the Joint Committee on Immunization and Immunization and four UK chief medical officers, in a bid to protect the largest number of people in the shortest time possible, narrowing the gap between the first and second doses of the vaccine Agreed upon.